<DOC>
	<DOC>NCT00004381</DOC>
	<brief_summary>OBJECTIVES: I. Compare the efficacy of preventive vs. therapeutic tin mesoporphyrin in direct Coombs' test-positive ABO hemolytic disease of the newborn and glucose-6-phosphate dehydrogenase deficiency in infants living in Greece. II. Assess the safety of tin mesoporphyrin in high-risk newborns.</brief_summary>
	<brief_title>Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia</brief_title>
	<detailed_description>PROTOCOL OUTLINE: Patients are stratified by gestational age and sex, and randomly assigned in pairs per stratum. One group receives a preventive dose of tin mesoporphyrin. Another group receives a therapeutic dose of tin mesoporphyrin according to the plasma bilirubin concentration. Patients in either group may be treated concurrently with phototherapy or exchange transfusion if clinically indicated.</detailed_description>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Hyperbilirubinemia</mesh_term>
	<mesh_term>Erythroblastosis, Fetal</mesh_term>
	<mesh_term>Glucosephosphate Dehydrogenase Deficiency</mesh_term>
	<mesh_term>Tin mesoporphyrin</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Hyperbilirubinemia associated with either of the following: Direct Coombs' testpositive ABO hemolytic disease of the newborn Glucose6phosphate dehydrogenase deficiency Prior/Concurrent Therapy No maternal phenobarbital in last month of pregnancy Patient Characteristics Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: No congenital renal abnormality Cardiovascular: No congenital heart abnormality Pulmonary: No asphyxia requiring assisted ventilation at delivery Other: Gestational age more than 210 days Birth weight at least 1500 g No other major congenital abnormality, i.e.: Central nervous system Chromosomal Gastrointestinal No evident or suspected congenital infection, e.g.: Cytomegalovirus Herpes Rubella Syphilis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Hours</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>glucose-6-phosphate dehydrogenase deficiency</keyword>
	<keyword>hematologic disorders</keyword>
	<keyword>hemolytic disease</keyword>
	<keyword>hyperbilirubinemia</keyword>
	<keyword>neonatal disorders</keyword>
	<keyword>rare disease</keyword>
</DOC>